Corsera Health is at the forefront of innovation in the Biotechnology and Pharmaceutical sectors, with a mission centered on Extending Healthspan by Predicting and Preventing Cardiovascular Disease. Founded in 2024, this cutting-edge company merges pioneering advances in RNAi therapeutics with profound expertise in cardiovascular medicine.
Led by industry veterans, Corsera Health leverages decades of innovation to transform cardiovascular disease management. Its strategic approach spans efficient manufacturing, robust evidence generation, and a disruptive commercialization model, all aimed at redefining patient outcomes.
In January 2026, the company secured a significant $80.00M Series A investment, marking a pivotal milestone in its growth journey. This funding round, driven by investors such as Forbion, Population Health Partners, and renowned RNAi expert John Maraganore, underscores strong confidence in the company’s potential to revolutionize cardiovascular care.
